Nothing Special   »   [go: up one dir, main page]

CY1119893T1 - Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων - Google Patents

Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων

Info

Publication number
CY1119893T1
CY1119893T1 CY20181100146T CY181100146T CY1119893T1 CY 1119893 T1 CY1119893 T1 CY 1119893T1 CY 20181100146 T CY20181100146 T CY 20181100146T CY 181100146 T CY181100146 T CY 181100146T CY 1119893 T1 CY1119893 T1 CY 1119893T1
Authority
CY
Cyprus
Prior art keywords
conjugates
agents
analogs
release
interlinks
Prior art date
Application number
CY20181100146T
Other languages
English (en)
Inventor
Patrick Henry Beusker
Rudy Gerardus Elisabeth Coumans
Ronald Christiaan Elgersma
Wiro Michael Petrus Bernardus Menge
Johannes Albertus Frederikus Joosten
Henri Johannes Spijker
Franciscus Marinus Hendrikus GROOT de
Original Assignee
Syntarga B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntarga B.V. filed Critical Syntarga B.V.
Publication of CY1119893T1 publication Critical patent/CY1119893T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αυτή αφορά σε νέα ανάλογα του DNA-αλκυλιωτικού παράγοντα CC-1065 και προϊόντα σύζευξης αυτών. Περαιτέρω, η εφεύρεση αυτή αφορά ενδιάμεσα για την παρασκευή των εν λόγω παραγόντων και προϊόντων σύζευξης. Τα προϊόντα σύζευξης είναι σχεδιασμένα για να απελευθερώνουν το (πολλαπλό) ωφέλιμο φορτίο αυτών μετά από ένα ή περισσότερα στάδια ενεργοποίησης ή/και σε ένα ρυθμό και χρονικό διάστημα που ελέγχεται με το προϊόν σύζευξης, για να απελευθερώνεται εκλεκτικώς ή/και να απελευθερώνεται με ελεγχόμενο τρόπο ένας ή περισσότεροι από τους εν λόγω παράγοντες αλκυλίωσης DNA. Οι παράγοντες, προϊόντα σύζευξης και ενδιάμεσα μπορεί να χρησιμοποιηθούν για να θεραπεύεται ασθένεια η οποία χαρακτηρίζεται από ανεπιθύμητο πολλαπλασιασμό (κυττάρου). Ως παράδειγμα, οι παράγοντες και τα προϊόντα σύζευξης της εφεύρεσης αυτής μπορεί να χρησιμοποιηθούν για να θεραπεύεται ένας όγκος.
CY20181100146T 2010-04-21 2018-02-06 Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων CY1119893T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32643710P 2010-04-21 2010-04-21
US42182410P 2010-12-10 2010-12-10
EP11720340.6A EP2560645B1 (en) 2010-04-21 2011-04-21 Conjugates of cc-1065 analogs and bifunctional linkers

Publications (1)

Publication Number Publication Date
CY1119893T1 true CY1119893T1 (el) 2018-06-27

Family

ID=44343209

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161100997T CY1118072T1 (el) 2010-04-21 2016-10-06 Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων
CY20181100146T CY1119893T1 (el) 2010-04-21 2018-02-06 Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY20201100778T CY1124632T1 (el) 2010-04-21 2020-08-20 Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100997T CY1118072T1 (el) 2010-04-21 2016-10-06 Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100778T CY1124632T1 (el) 2010-04-21 2020-08-20 Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες

Country Status (23)

Country Link
US (3) US9629924B2 (el)
EP (3) EP3108886B1 (el)
JP (2) JP6009434B2 (el)
KR (3) KR101901555B1 (el)
CN (1) CN106749665B (el)
AU (2) AU2011243294C1 (el)
BR (1) BR112012026953A8 (el)
CA (2) CA2956934C (el)
CY (3) CY1118072T1 (el)
DK (3) DK3108886T3 (el)
ES (3) ES2660428T3 (el)
HR (3) HRP20161339T1 (el)
HU (3) HUE030846T2 (el)
LT (3) LT3108886T (el)
MX (1) MX336853B (el)
NO (1) NO3056203T3 (el)
PL (3) PL2560645T3 (el)
PT (3) PT3056203T (el)
RU (2) RU2578719C9 (el)
TR (1) TR201802539T4 (el)
UA (1) UA112291C2 (el)
WO (1) WO2011133039A2 (el)
ZA (1) ZA201208282B (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708771B8 (pt) 2006-03-10 2021-05-25 Wyeth Corp anticorpos anti-5t4, conjugado de fármaco/ anticorpo para liberação de fármaco, usos dos mesmos e ácido nucléico isolado codificando uma região variável de cadeias pesada e leve anti-5t4
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
CN106967062A (zh) 2008-11-03 2017-07-21 辛塔佳股份有限公司 新型cc‑1065类似物及其缀合物
ES2660428T3 (es) 2010-04-21 2018-03-22 Syntarga B.V. Conjugados de análogos de CC-1065 y conectores bifuncionales
PT2766048E (pt) 2012-10-12 2015-02-25 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CA2896690A1 (en) 2012-12-21 2014-06-26 Abgenomics International Inc. Hydrophilic self-immolative linkers and conjugates thereof
AR096287A1 (es) * 2013-03-13 2015-12-23 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
PT3092010T (pt) * 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
PT2948183T (pt) 2014-01-10 2016-07-13 Univ Yale Conjugados anticorpo-fármaco de duocarmicina para utilização no tratamento de cancro do endométrio
RU2689779C2 (ru) 2014-01-10 2019-05-29 Синтон Байофармасьютикалс Б. В. Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
JP6517240B2 (ja) * 2014-05-22 2019-05-22 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
JP6275881B2 (ja) 2014-06-05 2018-02-07 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． デュオカルマイシンのプロドラッグを製造するための改良された方法
EP3157960A4 (en) 2014-06-20 2018-01-24 BioAlliance C.V. Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
RU2017101331A (ru) * 2014-06-20 2018-07-23 Абгеномикс Интернэшнл Инк. Конъюгаты антитело к her2 - лекарственное средство
WO2016001485A1 (en) 2014-06-30 2016-01-07 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
HUE053799T2 (hu) 2015-07-10 2021-07-28 Byondis Bv Antitest-duokarmicin gyógyszer-konjugátumokat tartalmazó készítmények
AU2016328461B2 (en) * 2015-09-22 2021-04-08 Byondis B.V. SYD985 treatment of T-DM1 refractory cancer patients
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
LT3380122T (lt) * 2015-11-24 2021-10-11 Byondis B.V. Antikūnai prieš 5t4 ir antikūno-vaistų konjugatai
KR20180117102A (ko) 2016-01-08 2018-10-26 바이오얼라이언스 씨.브이. 사가 항-psgl-1 항체 및 이들의 용도
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2818575T3 (es) 2016-02-12 2021-04-13 Byondis Bv Reducción selectiva de anticuerpos con modificación de cisteínas
IL262396B2 (en) 2016-04-15 2023-09-01 Macrogenics Inc New b7-h3 binding molecules, drug-antibody conjugates and their uses
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR102493853B1 (ko) * 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
DK3525826T3 (da) 2016-10-11 2020-08-24 Byondis Bv Ikke-lineære selvofrende linkere og konjugater deraf
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US10815194B2 (en) 2016-11-14 2020-10-27 Byondis B.V. Process for the preparation of mono-protected α,ω-diamino alkanes
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN110831976A (zh) 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
KR102312910B1 (ko) 2017-08-18 2021-10-15 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019081455A1 (en) 2017-10-23 2019-05-02 Mablink Bioscience LIGAND-MEDICINAL CONJUGATE COMPRISING A UNIQUE MOLECULAR WEIGHT POLYSARCOSIN
HUE055305T2 (hu) * 2017-11-24 2021-11-29 Byondis Bv Javított eljárás vc-seco linker-hatóanyag szintézisére
CA3083345A1 (en) 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3866785A1 (en) 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
PT3876997T (pt) 2018-11-09 2022-11-11 Byondis Bv Composições de conjugados anticorpo-fármaco contendo duocarmicina filtrável e métodos relacionados
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4100024A1 (en) 2020-02-06 2022-12-14 Byondis B.V. Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate
AU2021306557A1 (en) 2020-07-06 2023-02-02 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20220008511A1 (en) * 2020-07-12 2022-01-13 Henry J. Smith Tumor treatment using cytokines and cancer drugs
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
AU2022254291A1 (en) 2021-04-08 2023-10-12 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
IL309249A (en) 2021-06-28 2024-02-01 Byondis Bv Conjugates including phosphoantigens and their use in therapy
AU2022425491A1 (en) 2021-12-30 2024-07-04 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
AU2023271317A1 (en) 2022-05-16 2024-11-07 Byondis B.V. Novel masked antibodies
WO2024133374A1 (en) 2022-12-22 2024-06-27 Byondis B.V. Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098331A (en) 1981-05-12 1982-11-17 Sangamo Weston Controls Parallel motion displacement transducers
CA1238907A (en) 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
AU617304B2 (en) 1986-12-19 1991-11-28 Pharmacia & Upjohn Company Novel cc-1065 analogs
WO1990002746A1 (en) 1988-09-12 1990-03-22 The Upjohn Company Novel cc-1065 analogs having two cpi subunits
CA2078118C (en) 1990-04-25 1999-11-16 Paul A. Aristoff Cc-1065 analogs
ES2149768T3 (es) * 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
JP3514490B2 (ja) * 1992-08-21 2004-03-31 杏林製薬株式会社 トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
AU689566B2 (en) 1994-04-01 1998-04-02 Kyowa Hakko Kogyo Co. Ltd. DC-89 derivatives
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
DE19503320A1 (de) 1995-02-02 1996-08-08 Boehringer Mannheim Gmbh Neue Benzodiazepinkonjugate
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
NZ321172A (en) 1995-10-03 2000-02-28 Scripps Research Inst CBI analogs of CC-1065 and the duocarmycins
ES2244991T3 (es) 1996-03-08 2005-12-16 The Scripps Research Institute Analogosmcbi de cc-1065 y las duocarmicinas.
US5843937A (en) * 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
WO1997045411A1 (en) 1996-05-31 1997-12-04 The Scripps Research Institute Analogs of cc-1065 and the duocarmycins
JP4155598B2 (ja) * 1996-09-12 2008-09-24 オークランド ユニサーヴィシズ リミテッド 抗癌剤としての縮合ｎ−アシルインドール
GB9625913D0 (en) 1996-12-13 1997-01-29 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their seco precursors,and their use as prodrugs
WO1998025900A1 (fr) 1996-12-13 1998-06-18 Shionogi & Co., Ltd. Composes presentant une activite antitumorale
EP0983248B1 (en) 1997-05-22 2004-07-14 The Scripps Research Institute Analogs of duocarmycin and cc-1065
WO1999019298A1 (en) 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
US20030036629A1 (en) 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
AU2001273983A1 (en) 2000-05-02 2001-11-12 Lutz F. Tietze Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
AU2001262974A1 (en) 2000-05-03 2001-11-12 The Scripps Research Institute Dna alkylating agent and activation thereof
CN1315805C (zh) 2000-09-19 2007-05-16 斯皮罗根公司 Cc－1065和多卡米新的非手性类似物的组合物及其使用方法
WO2002059122A1 (en) 2001-01-24 2002-08-01 Auckland Uniservices Limited ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO[3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM
ES2287256T3 (es) 2001-02-22 2007-12-16 School Of Pharmacy, University Of London Indolinas y tetrahidroquinolina como profarmacos para el tratamiento de tumores.
JP4862120B2 (ja) 2001-02-22 2012-01-25 ユニヴァーシティ オブ ブラッドフォード 腫瘍治療のためのプロドラッグとしてのベンズ−インドールおよびベンゾ−キノリン誘導体
JP2004529887A (ja) 2001-02-22 2004-09-30 スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン 腫瘍治療のためのプロドラッグとしてのピロロ−インドールおよびピロロ−キノリン誘導体
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2448319C (en) 2001-05-31 2010-07-27 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
AU2003228173A1 (en) 2002-05-17 2003-12-02 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-(ring fused indol-5-yl(amine-derived)) compounds and analogues thereof, and to products obtained therefrom
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP2517729A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US20070037739A1 (en) 2003-02-03 2007-02-15 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
EP1594542B1 (en) 2003-02-20 2010-06-30 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer
US20050026987A1 (en) 2003-05-13 2005-02-03 The Scripps Research Institute CBI analogues of the duocarmycins and CC-1065
WO2005032594A2 (en) * 2003-10-03 2005-04-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alkylators linked to polyamides as dna binding agents
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
ZA200609638B (en) 2004-04-21 2008-02-27 Alza Corp Polymer conjugate releasable under mild thiolytic conditions
US20050239864A1 (en) 2004-04-23 2005-10-27 Yuqiang Wang Novel tumor-selective chemotherapeutic agents
EP1747021B1 (en) 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
AU2005259487A1 (en) 2004-06-30 2006-01-12 Novartis Ag Conjugates of antibody and duoarmycin derivatives as antitumor agents
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine-manipulated antibodies and conjugates
US20100041617A1 (en) * 2004-09-27 2010-02-18 Jane Trepel Modulating mxa expression
NZ536107A (en) * 2004-10-22 2007-06-29 Auckland Uniservices Ltd Nitrobenzindoles and their use in cancer therapy
CA2598956A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
PT1940789E (pt) * 2005-10-26 2012-02-01 Medarex Inc Métodos e compostos para preparar análogos cc-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
RU2489423C2 (ru) * 2006-02-02 2013-08-10 Синтарга Б.В. Водорастворимые аналоги сс-1065 и их конъюгаты
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
CA2995467C (en) 2006-11-01 2020-03-10 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2121667B1 (en) 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Chemical linkers with single amino acids and conjugates thereof
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA2723883C (en) * 2007-11-13 2014-10-28 The Scripps Research Institute Cbi derivatives subject to reductive activation
AR069903A1 (es) 2007-11-30 2010-03-03 Medarex Inc Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
MX2010005683A (es) 2007-11-30 2010-06-11 Bristol Myers Squibb Co Conjugados de anticuerpos anti-rg-1.
US20090162372A1 (en) * 2007-11-30 2009-06-25 Medarex, Inc. Fibronectin ed-b antibodies, conjugates thereof, and methods of use
CA2706926A1 (en) 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
ES2648122T3 (es) 2008-04-30 2017-12-28 Immunogen, Inc. Reticulantes y sus usos
NZ571028A (en) 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
WO2010033733A1 (en) * 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
CN106967062A (zh) 2008-11-03 2017-07-21 辛塔佳股份有限公司 新型cc‑1065类似物及其缀合物
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
ES2660428T3 (es) * 2010-04-21 2018-03-22 Syntarga B.V. Conjugados de análogos de CC-1065 y conectores bifuncionales
CN103858003B (zh) 2011-09-29 2018-06-22 西雅图基因公司 蛋白偶联的试剂化合物的整体分子量测定
UA123092C2 (uk) 2011-10-14 2021-02-17 Дженентек, Інк. Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
PT3092010T (pt) 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
PT2948183T (pt) 2014-01-10 2016-07-13 Univ Yale Conjugados anticorpo-fármaco de duocarmicina para utilização no tratamento de cancro do endométrio
RU2689779C2 (ru) 2014-01-10 2019-05-29 Синтон Байофармасьютикалс Б. В. Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
JP6517240B2 (ja) 2014-05-22 2019-05-22 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
JP6275881B2 (ja) 2014-06-05 2018-02-07 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． デュオカルマイシンのプロドラッグを製造するための改良された方法
WO2016046173A1 (en) 2014-09-22 2016-03-31 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins

Also Published As

Publication number Publication date
HUE050508T2 (hu) 2020-12-28
RU2578719C2 (ru) 2016-03-27
LT2560645T (lt) 2016-10-10
RU2578719C9 (ru) 2016-10-10
WO2011133039A2 (en) 2011-10-27
EP3108886A3 (en) 2017-03-22
JP2016183156A (ja) 2016-10-20
DK2560645T3 (en) 2016-10-10
JP6193433B2 (ja) 2017-09-06
JP6009434B2 (ja) 2016-10-19
LT3108886T (lt) 2020-08-25
CA2796712A1 (en) 2011-10-27
HRP20201446T1 (hr) 2021-03-05
RU2012149448A (ru) 2014-05-27
KR101747478B1 (ko) 2017-06-14
CY1124632T1 (el) 2022-03-24
RU2730502C2 (ru) 2020-08-24
CN106749665A (zh) 2017-05-31
PT2560645T (pt) 2016-10-24
CA2956934C (en) 2019-07-09
WO2011133039A3 (en) 2012-04-12
AU2011243294C1 (en) 2015-12-03
US20170274090A1 (en) 2017-09-28
AU2011243294A1 (en) 2012-11-15
KR20130066622A (ko) 2013-06-20
TR201802539T4 (tr) 2018-03-21
BR112012026953A2 (pt) 2018-07-10
EP3056203B1 (en) 2017-12-13
HUE030846T2 (en) 2017-06-28
AU2011243294B2 (en) 2015-06-04
CA2956934A1 (en) 2011-10-27
CY1118072T1 (el) 2017-06-28
ES2660428T3 (es) 2018-03-22
PL3056203T3 (pl) 2018-06-29
CN103118679A (zh) 2013-05-22
ZA201208282B (en) 2014-01-29
US9629924B2 (en) 2017-04-25
PT3108886T (pt) 2020-08-27
US20170333567A1 (en) 2017-11-23
NO3056203T3 (el) 2018-05-12
PT3056203T (pt) 2018-02-15
PL3108886T3 (pl) 2021-01-11
RU2016101244A (ru) 2017-07-21
AU2015213336A1 (en) 2015-09-03
EP3108886B1 (en) 2020-06-17
PL2560645T3 (pl) 2017-01-31
AU2015213336B2 (en) 2016-07-21
EP3056203A1 (en) 2016-08-17
KR20180029083A (ko) 2018-03-19
JP2013525347A (ja) 2013-06-20
CA2796712C (en) 2017-02-28
HUE036912T2 (hu) 2018-08-28
HRP20180209T1 (hr) 2018-03-09
US20180147289A9 (en) 2018-05-31
EP2560645B1 (en) 2016-07-13
CN106749665B (zh) 2021-03-26
KR101901555B1 (ko) 2018-09-21
HRP20161339T1 (hr) 2016-11-18
MX2012012176A (es) 2012-12-17
DK3108886T3 (da) 2020-08-10
KR20170027880A (ko) 2017-03-10
LT3056203T (lt) 2018-03-26
EP2560645A2 (en) 2013-02-27
RU2016101244A3 (el) 2019-07-24
US11052155B2 (en) 2021-07-06
ES2815678T3 (es) 2021-03-30
HRP20201446T8 (hr) 2021-08-20
DK3056203T3 (da) 2018-01-29
BR112012026953A8 (pt) 2022-11-22
US20130224227A1 (en) 2013-08-29
EP3108886A2 (en) 2016-12-28
US20180133316A9 (en) 2018-05-17
ES2594952T3 (es) 2016-12-27
MX336853B (es) 2016-01-19
UA112291C2 (uk) 2016-08-25

Similar Documents

Publication Publication Date Title
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY1119696T1 (el) Cc-1065 αναλογα και τα συζευγματα αυτων
CY1123831T1 (el) Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1122636T1 (el) Συνθεσεις για τη συνδεση στοιχειων με δακτυλους ψευδαργυρου
CY1123774T1 (el) Στελεχη shigella me υπερφυσαλιδωση
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CY1119476T1 (el) Αναστολεις της απομεθυλασης ιστονης
CY1119006T1 (el) Ινδολια
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1120707T1 (el) Anti-cd28 εξανθρωπισμενα αντισωματα
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
CY1123581T1 (el) Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων
CY1119605T1 (el) Παραγωγα 5-αρυλο ή 5-ετεροαρυλο υποκατεστημενου 3-υδροξυπυριδιν-2-υλ-καρβονυλαμινο-αλκανοϊκου οξεος και αλατα αυτων καθως και παρασκευη τους απο τα αντιστοιχα παραγωγα 3-υδροξυ-πικολινικου οξεος
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1117752T1 (el) Τετρακυκλικη ενωση
CY1118681T1 (el) Αναστολεις νεπριλυσινης
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos